AAIC 2026: Imaging Advances

Imaging Advances at AAIC 2026

Neuroimaging advances presented at AAIC 2026 demonstrated significant progress in both PET tracers and MRI techniques for [Alzheimer's disease](/diseases/alzheimers-disease) (AD) diagnosis, staging, and treatment monitoring.

PET Tracer Advances

Tau PET Imaging

Second-Generation Tau Tracers

New [tau](/proteins/tau) PET tracers with improved properties were highlighted[@fleisher2024]:

• Improved specificity: Reduced off-target binding in basal ganglia and white matter
• Broadened disease utility: Applicability to primary age-related tauopathy (PART) and chronic traumatic encephalopathy (CTE)
• Kinetic modeling: Simplified quantification methods for clinical use

Tau Pet in Clinical Trials

Tau PET quantification methods for anti-amyloid and anti-tau therapeutics:

• Regional tau burden as stratification biomarker
• Change metrics for treatment response assessment
• Correlation with cognitive outcomes

Amyloid PET Innovations

Novel Tracers

Next-generation amyloid PET tracers offer advantages[@rowe2023]:

• Faster kinetics enabling same-day imaging
• Improved signal-to-noise ratio
• Reduced non-specific binding

Quantitative Approaches

Standardization advances in amyloid PET:

• Centiloid scale adoption across studies
• Harmonized SUVr methods
• Longitudinal change thresholds

Novel Target Tracers

Synaptic PET Imaging

Emerging tracers for synaptic density[@finnema2020]:

Imaging Advances at AAIC 2026

Neuroimaging advances presented at AAIC 2026 demonstrated significant progress in both PET tracers and MRI techniques for [Alzheimer's disease](/diseases/alzheimers-disease) (AD) diagnosis, staging, and treatment monitoring.

PET Tracer Advances

Tau PET Imaging

Second-Generation Tau Tracers

New [tau](/proteins/tau) PET tracers with improved properties were highlighted[@fleisher2024]:

• Improved specificity: Reduced off-target binding in basal ganglia and white matter
• Broadened disease utility: Applicability to primary age-related tauopathy (PART) and chronic traumatic encephalopathy (CTE)
• Kinetic modeling: Simplified quantification methods for clinical use

Tau Pet in Clinical Trials

Tau PET quantification methods for anti-amyloid and anti-tau therapeutics:

• Regional tau burden as stratification biomarker
• Change metrics for treatment response assessment
• Correlation with cognitive outcomes

Amyloid PET Innovations

Novel Tracers

Next-generation amyloid PET tracers offer advantages[@rowe2023]:

• Faster kinetics enabling same-day imaging
• Improved signal-to-noise ratio
• Reduced non-specific binding

Quantitative Approaches

Standardization advances in amyloid PET:

• Centiloid scale adoption across studies
• Harmonized SUVr methods
• Longitudinal change thresholds

Novel Target Tracers

Synaptic PET Imaging

Emerging tracers for synaptic density[@finnema2020]:

• [^11C]UCB-J: SV2A imaging showing synaptic loss in AD
• Correlation with cognitive performance
• Potential for treatment monitoring

Neuroinflammation Imaging

TSPO and novel microglial imaging targets:

• Third-generation TSPO tracers with reduced variability
• P2X7 receptor imaging for targeted neuroinflammation
• Correlation with disease progression

MRI Advances

Advanced MRI Techniques

Quantitative MRI

New quantitative approaches for clinical implementation[@jack2023]:

• QSM (Quantitative Susceptibility Mapping): Iron deposition tracking
• MT (Magnetization Transfer): Myelin integrity assessment
• Diffusion MRI: Microstructural change detection

Functional MRI

Advancements in fMRI for AD:

• Resting-state connectivity alterations in preclinical AD
• Default mode network (DMN) changes as early markers
• Task-based fMRI for cognitive reserve assessment

Amyloid and Tau MRI

MRI-Based Tau Detection

Emerging techniques for tau pathology visualization:

• T1rho imaging sensitive to tau accumulation
• MT saturation changes correlating with tau
• Diffusion changes in tau-affected regions

Amyloid-CEST MRI

Chemical exchange saturation transfer for amyloid detection:

• Promising results in human studies
• Correlation with PET amyloid imaging
• Potential for widespread clinical use

Vascular Imaging

7T MRI Advances

Ultra-high-field MRI capabilities:

• Improved resolution for small vessel detection
• Leptomeningeal collaterals visualization
• Perivascular space characterization

Advanced Vessel Wall Imaging

Vessel wall MRI innovations:

• Distinguishing amyloid angiopathy from vasculitis
• Plaque inflammation detection
• Treatment response monitoring

Hybrid Imaging

PET/MRI Integration

Combined PET/MRI advances presented at AAIC 2026:

• Simultaneous acquisition protocols
• Attenuation correction improvements
• Multiparametric biomarkers from single session

Tau-PET and Structural MRI

Combined analysis approaches:

• Tau burden prediction of atrophy patterns
• Regional vulnerability mapping
• Progression modeling

Clinical Translation

Standardization Efforts

Critical progress toward clinical implementation:

• Automated analysis pipelines (FreeSurfer, FSL, ANTs)
• Harmonization across scanner vendors
• Quality control protocols

FDA-Approved Tracers

Current clinical tracers and their applications:

• [^18F]Florbetapir (Amyvid): Amyloid PET](/biomarkers/florbetapir)
• [^18F]Flutemetamol (Vizamyl): Amyloid PET](/biomarkers/flutemetamol)
• [^18F]Florbetaben (Neuraceq): Amyloid PET](/biomarkers/florbetaben)
• [^18F]Flortaucipir (Tauvid): Tau PET

Research Applications

Biomarker Integration

Multimodal biomarker approaches:

• Amyloid PET + tau PET + MRI combinations
• Fluid biomarker correlation with imaging
• Prediction models using integrated biomarkers

Clinical Trial Applications

Imaging endpoints in clinical trials:

• Amyloid clearance rates
• Tau spreading inhibition
• Atrophy modification

Future Directions

The imaging field is advancing toward:

Overview

This page provides information about AAIC 2026: Imaging Advances.

See Also

• [NeuroWiki Home](/home)

References